Cartesian Therapeutics, Inc.RNACEarnings & Financial Report
Cartesian Therapeutics is a clinical-stage biopharmaceutical company specializing in RNA-engineered cell therapies for oncology, autoimmune disorders and rare diseases. It operates primarily in the U.S. market, focusing on next-generation CAR-T and immune cell therapies, advancing multiple candidates through mid-stage clinical trials with leading medical research partners.
Revenue
$8.3M
Gross Profit
N/A
Operating Profit
$-36.3M
Net Profit
$-177.7M
Gross Margin
N/A
Operating Margin
-439.5%
Net Margin
-2149.3%
YoY Growth
-50.8%
EPS
$-41.55
Cartesian Therapeutics, Inc. Q4 FY2023 Financial Summary
Cartesian Therapeutics, Inc. reported revenue of $8.3M (down 50.8% YoY) for Q4 FY2023, with a net profit of $-177.7M (down 3114.7% YoY) (-2149.3% margin).
Key Financial Metrics
| Total Revenue | $8.3M |
|---|---|
| Net Profit | $-177.7M |
| Gross Margin | N/A |
| Operating Margin | -439.5% |
| Report Period | Q4 FY2023 |
Cartesian Therapeutics, Inc. Annual Revenue by Year
Cartesian Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $38.3M).
| Year | Annual Revenue |
|---|---|
| 2024 | $38.3M |
| 2023 | $26.0M |
| 2022 | $110.8M |
Cartesian Therapeutics, Inc. Quarterly Revenue & Net Profit History
Cartesian Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $0 | — | $-92.6M | N/A |
| Q3 FY2025 | $0 | — | $-35.9M | N/A |
| Q2 FY2025 | $0 | — | $15.9M | N/A |
| Q4 FY2024 | $-836.0K | -110.1% | $-10.3M | 1226.4% |
| Q3 FY2024 | $0 | — | $-24.2M | N/A |
| Q2 FY2024 | $33.3M | +533.9% | $13.8M | 41.6% |
| Q1 FY2024 | $5.8M | -1.7% | $-56.8M | -973.0% |
| Q4 FY2023 | $8.3M | -50.8% | $-177.7M | -2149.3% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $8.3M | $5.8M | $33.3M | $0 | $-836000 | $0 | $0 | $0 |
| YoY Growth | -50.8% | -1.7% | 533.9% | N/A | -110.1% | N/A | N/A | N/A |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $305.1M | $325.2M | $347.7M | $455.3M | $435.0M | $388.9M | $372.7M | $296.4M |
| Liabilities | $444.7M | $442.0M | $449.2M | $454.6M | $441.8M | $391.4M | $408.5M | $422.7M |
| Equity | $-440.2M | $-116.8M | $-101.5M | $752000 | $-6.8M | $-2.5M | $-35.8M | $-126.2M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-23.3M | $-15.9M | $-14.4M | $13.7M | $-7.0M | $-17.5M | $-15.6M | $-17.7M |